Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Cluster Analysis to Identify Apnea-Hypopnea Syndrome Phenotypes: Where Are We Heading?

Silveira MG, Lloberes P.

Arch Bronconeumol. 2020 Jan 2. pii: S0300-2896(19)30598-8. doi: 10.1016/j.arbres.2019.11.023. [Epub ahead of print] English, Spanish. No abstract available.

PMID:
31902627
2.

Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis.

Ali AH, Tabibian JH, Nasser-Ghodsi N, Lennon RJ, DeLeon T, Borad MJ, Hilscher M, Silveira MG, Carey EJ, Lindor KD.

Hepatology. 2018 Jun;67(6):2338-2351. doi: 10.1002/hep.29730. Epub 2018 Apr 19.

PMID:
29244227
3.

Investigational drugs in phase II clinical trials for primary biliary cholangitis.

Silveira MG, Lindor KD.

Expert Opin Investig Drugs. 2017 Oct;26(10):1115-1121. doi: 10.1080/13543784.2017.1371135. Epub 2017 Aug 31. Review.

PMID:
28836457
4.

Tracheobronchopathia osteochondroplastica.

Silveira MGM, Castellano MVCO, Fuzi CE, Coletta ENAM, Spinosa GN.

J Bras Pneumol. 2017 Mar-Apr;43(2):151-153. doi: 10.1590/S1806-37562016000000143. English, Portuguese.

5.

Lung transplantation in systemic sclerosis: A single center cohort study.

Fernández-Codina A, Berastegui C, Pinal-Fernández I, Silveira MG, López-Meseguer M, Monforte V, Guillén-Del Castillo A, Simeón-Aznar CP, Fonollosa-Plà V, Solé J, Bravo-Masgoret C, Román-Broto A.

Joint Bone Spine. 2018 Jan;85(1):79-84. doi: 10.1016/j.jbspin.2017.03.012. Epub 2017 Apr 11.

PMID:
28408277
6.

Adaptive Servoventilation Device Software in the Assessment of Residual Respiratory Events in Patients With Central or Complex Apnoeas.

Silveira MG, Sampol G, Cambrodi R, Ferre À, Lloberes P.

Arch Bronconeumol. 2017 Aug;53(8):455-457. doi: 10.1016/j.arbres.2016.11.026. Epub 2017 Feb 13. English, Spanish. No abstract available.

PMID:
28209445
7.

Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C.

Davitkov P, Chandar AK, Hirsch A, Compan A, Silveira MG, Anthony DD, Smith S, Gideon C, Bonomo RA, Falck-Ytter Y.

PLoS One. 2016 Oct 14;11(10):e0163945. doi: 10.1371/journal.pone.0163945. eCollection 2016.

8.

A Randomized, Placebo-Controlled Clinical Trial of Efficacy and Safety: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis.

Silveira MG, Gossard AA, Stahler AC, Jorgensen RA, Petz JL, Ali AH, Lindor KD.

Am J Ther. 2017 Mar/Apr;24(2):e167-e176. doi: 10.1097/MJT.0000000000000387.

PMID:
27148676
9.

Anti-MDA5 dermatomyositis and progressive interstitial pneumonia.

Silveira MG, Selva-O'Callaghan A, Ramos-Terrades N, Arredondo-Agudelo KV, Labrador-Horrillo M, Bravo-Masgoret C.

QJM. 2016 Jan;109(1):49-50. doi: 10.1093/qjmed/hcv068. Epub 2015 Mar 16. No abstract available.

PMID:
25784769
10.

Assessment of Myocardial Ischemia in Obese Individuals Undergoing Physical Stress Echocardiography (PSE).

Silveira MG, Sousa AC, Santos MA, Tavares Ida S, Andrade SM, Melo LD, Andrade LS, Santos EL, Oliveira JL.

Arq Bras Cardiol. 2015 May;104(5):394-400. doi: 10.5935/abc.20150006. Epub 2015 Feb 13. English, Portuguese.

11.

Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.

Silveira MG, Lindor KD.

Expert Opin Pharmacother. 2014 Feb;15(3):365-72. doi: 10.1517/14656566.2014.873404. Epub 2014 Jan 2. Review.

PMID:
24382005
12.

IgG4-associated cholangitis.

Silveira MG.

Clin Liver Dis. 2013 May;17(2):255-68. doi: 10.1016/j.cld.2012.11.007. Epub 2012 Dec 20. Review.

PMID:
23540501
13.

Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis.

Momah N, Silveira MG, Jorgensen R, Sinakos E, Lindor KD.

Liver Int. 2012 May;32(5):790-5. doi: 10.1111/j.1478-3231.2011.02678.x. Epub 2011 Dec 4.

PMID:
22136310
14.

Long-term outcomes of patients with primary biliary cirrhosis and hepatocellular carcinoma.

Imam MH, Silveira MG, Sinakos E, Gossard AA, Jorgensen R, Keach J, DeCook AC, Lindor KD.

Clin Gastroenterol Hepatol. 2012 Feb;10(2):182-5. doi: 10.1016/j.cgh.2011.09.013. Epub 2011 Oct 1.

PMID:
21963959
15.

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.

Eaton JE, Silveira MG, Pardi DS, Sinakos E, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Lindor KD.

Am J Gastroenterol. 2011 Sep;106(9):1638-45. doi: 10.1038/ajg.2011.156. Epub 2011 May 10.

16.

Varices in early histological stage primary biliary cirrhosis.

Ali AH, Sinakos E, Silveira MG, Jorgensen RA, Angulo P, Lindor KD.

J Clin Gastroenterol. 2011 Aug;45(7):e66-71. doi: 10.1097/MCG.0b013e3181f18c4e.

PMID:
20856137
17.

American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis.

Silveira MG, Brunt EM, Heathcote J, Gores GJ, Lindor KD, Mayo MJ.

Hepatology. 2010 Jul;52(1):349-59. doi: 10.1002/hep.23637. No abstract available.

PMID:
20578151
18.

Comparing the simplified and international autoimmune hepatitis group criteria in primary sclerosing cholangitis.

Chandok N, Silveira MG, Lindor KD.

Gastroenterol Hepatol (N Y). 2010 Feb;6(2):108-12.

19.

Hepatic fibrosis and the renin-angiotensin system.

Abbas G, Silveira MG, Lindor KD.

Am J Ther. 2011 Nov;18(6):e202-8. doi: 10.1097/MJT.0b013e3181df8df5. Review.

PMID:
20535005
20.

Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis.

Treeprasertsuk S, Silveira MG, Petz JL, Lindor KD.

Am J Ther. 2011 Sep;18(5):375-81. doi: 10.1097/MJT.0b013e3181d7e1d3.

PMID:
20460985
21.

Recurrent primary biliary cirrhosis after liver transplantation.

Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH.

Am J Transplant. 2010 Apr;10(4):720-6. doi: 10.1111/j.1600-6143.2010.03038.x. Epub 2010 Feb 25. Review.

22.

Is there a role for tetrathiomolybdate in the treatment of primary biliary cirrhosis?

Silveira MG, Lindor KD.

Transl Res. 2010 Mar;155(3):120-2. doi: 10.1016/j.trsl.2009.10.006. Epub 2009 Dec 1. No abstract available.

PMID:
20171596
23.

38-year-old woman with abnormal liver enzymes and hyperlipidemia.

Silveira MG, Lindor KD.

Mayo Clin Proc. 2009 Jun;84(6):551-4. doi: 10.1016/S0025-6196(11)60587-9. No abstract available.

24.

Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease.

Silveira MG, Mendes FD, Diehl NN, Enders FT, Lindor KD.

Liver Int. 2009 Aug;29(7):1094-100. doi: 10.1111/j.1478-3231.2009.02003.x. Epub 2009 Mar 12.

PMID:
19291181
25.

Activity of ethanol-stressed Oenococcus oeni cells: a flow cytometric approach.

Da Silveira MG, Abee T.

J Appl Microbiol. 2009 May;106(5):1690-6. doi: 10.1111/j.1365-2672.2008.04136.x. Epub 2009 Feb 16.

26.

A patient with primary biliary cirrhosis and elevated LDL cholesterol.

Foley KF, Silveira MG, Hornseth JM, Lindor KD, McConnell JP.

Clin Chem. 2009 Jan;55(1):187-91; disscusion 191-2. doi: 10.1373/clinchem.2008.108720. No abstract available.

PMID:
19106186
27.

Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study.

Silveira MG, Torok NJ, Gossard AA, Keach JC, Jorgensen RA, Petz JL, Lindor KD.

Am J Gastroenterol. 2009 Jan;104(1):83-8. doi: 10.1038/ajg.2008.14.

PMID:
19098854
28.

Overlap syndromes with autoimmune hepatitis in chronic cholestatic liver diseases.

Silveira MG, Lindor KD.

Expert Rev Gastroenterol Hepatol. 2007 Dec;1(2):329-40. doi: 10.1586/17474124.1.2.329. Review.

PMID:
19072425
29.

Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis.

Silveira MG, Suzuki A, Lindor KD.

Hepatology. 2008 Oct;48(4):1149-56. doi: 10.1002/hep.22458.

PMID:
18785621
30.

Primary sclerosing cholangitis.

Silveira MG, Lindor KD.

Can J Gastroenterol. 2008 Aug;22(8):689-98. Review.

31.

Clinical features and management of primary sclerosing cholangitis.

Silveira MG, Lindor KD.

World J Gastroenterol. 2008 Jun 7;14(21):3338-49. Review.

32.

Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.

Silveira MG, Lindor KD.

Clin Liver Dis. 2008 May;12(2):425-43; x-xi. doi: 10.1016/j.cld.2008.02.008. Review.

PMID:
18456189
33.

High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.

Silveira MG, Lindor KD.

J Hepatol. 2008 May;48(5):692-4. doi: 10.1016/j.jhep.2008.02.002. Epub 2008 Feb 14. No abstract available.

34.

Quality of life and everyday activities in patients with primary biliary cirrhosis.

Selmi C, Gershwin ME, Lindor KD, Worman HJ, Gold EB, Watnik M, Utts J, Invernizzi P, Kaplan MM, Vierling JM, Bowlus CL, Silveira MG, Bossi I; USA PBC Epidemiology Group.

Hepatology. 2007 Dec;46(6):1836-43.

35.

Relationship among oxidative DNA damage, gastric mucosal density and the relevance of cagA, vacA and iceA genotypes of Helicobacter pylori.

Ladeira MS, Bueno RC, Dos Santos BF, Pinto CL, Prado RP, Silveira MG, Rodrigues MA, Bartchewsky W Jr, Pedrazzoli J Jr, Ribeiro ML, Salvadori DM.

Dig Dis Sci. 2008 Jan;53(1):248-55. Epub 2007 May 23.

PMID:
17520364
36.

Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes.

Silveira MG, Talwalkar JA, Angulo P, Lindor KD.

Am J Gastroenterol. 2007 Jun;102(6):1244-50. Epub 2007 Feb 23.

PMID:
17319931
37.

Effect of adaptation to ethanol on cytoplasmic and membrane protein profiles of Oenococcus oeni.

Silveira MG, Baumgärtner M, Rombouts FM, Abee T.

Appl Environ Microbiol. 2004 May;70(5):2748-55.

38.

Membrane fluidity adjustments in ethanol-stressed Oenococcus oeni cells.

Da Silveira MG, Golovina EA, Hoekstra FA, Rombouts FM, Abee T.

Appl Environ Microbiol. 2003 Oct;69(10):5826-32.

Supplemental Content

Loading ...
Support Center